Lewy Body Dementia (LBD)
Symptoms, Doctors, Treatments, Advances & More

Lewy Body Dementia (LBD) Overview

Save information for later
Sign Up

Learn About Lewy Body Dementia (LBD)

What is the definition of Lewy Body Dementia (LBD)?
Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected.
What are the alternative names for Lewy Body Dementia (LBD)?
  • Lewy body dementia
  • Autosomal dominant diffuse Lewy body disease
  • DLB
  • Diffuse Lewy body disease
  • Lewy body disease
Who are the top Lewy Body Dementia (LBD) Local Doctors?
Elite in Lewy Body Dementia (LBD)
Elite in Lewy Body Dementia (LBD)
Referral required

Muhammad Ali Parkinson Center

240 West Thomas Road, Suite 301, 
Phoenix, AZ 
602-406-6262
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Holly Shill is a Neurologist practicing medicine in Phoenix, Arizona. Dr. Shill is rated as an Elite provider by MediFind in the treatment of Lewy Body Dementia (LBD). She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Parkinson's Disease, Essential Tremor, Movement Disorders, Deep Brain Stimulation, and Tissue Biopsy. Dr. Shill is board certified in Psychiatry & Neurology (Neurology). Dr. Shill is currently accepting new patients.

Elite in Lewy Body Dementia (LBD)
Elite in Lewy Body Dementia (LBD)
Referral may be required
De Crespigny Park, 
London, ENG, GB 

Clive Ballard practices practicing medicine in London, United Kingdom. Mr. Ballard is rated as an Elite expert by MediFind in the treatment of Lewy Body Dementia (LBD). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Dementia, Alzheimer's Disease, Lewy Body Dementia (LBD), Parkinson's Disease, and Heart Bypass Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Lewy Body Dementia (LBD)
Elite in Lewy Body Dementia (LBD)
Referral may be required

Legacy Healthcare Services Inc

10515 W Santa Fe Dr, 
Sun City, AZ 
623-832-6530
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Shprecher is a Neurologist practicing medicine in Sun City, Arizona. Dr. Shprecher is rated as an Elite provider by MediFind in the treatment of Lewy Body Dementia (LBD). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Lewy Body Dementia (LBD), and Progressive Supranuclear Palsy. Dr. Shprecher is board certified in Neurology (American Board Of Neurology And Psychiatry). Dr. Shprecher is currently accepting new patients.

View All Doctors
What are the latest Lewy Body Dementia (LBD) Clinical Trials?
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Other

Summary: MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry t...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center